
    
      Efficacy index:

      After 12 weeks of treatment, the change difference of arteriosclerosis related biomarker
      between 4 modality groups.

      Pharmacokinetics:

      After 12 weeks of treatment, the study medication plasma concentration including of Probucol
      ,Cilostazol , Cilostazol metabolism OPC-13015 and OPC-13213 will be measured.

      Safety evaluation:

      Analysis the abnormality of Adverse Event, Vital Sign, Physical Examination, 12-lead ECG, and
      Laboratory Tests (including blood routine examination, routine urine analysis, blood
      biochemistry examination, glycosylated hemoglobin) in 4 modality groups.
    
  